Silencing KIF14 reverses acquired resistance to sorafenib in hepatocellular carcinoma

For nearly a decade, sorafenib has served as a first-line chemotherapeutic drug for the treatment of hepatocellular carcinoma (HCC), but it displays only limited efficacy against advanced drug-resistant HCC. Regorafenib, the first second-line drug approved for treatment after sorafenib failure, can...

Full description

Saved in:
Bibliographic Details
Published in:Aging (Albany NY)
Main Authors: Zhu, Qiankun, Ren, Haiyang, Li, Xiaodong, Qian, Bo, Fan, Shengjie, Hu, Fengli, Xu, Lishan, Zhai, Bo
Format: Artigo
Language:Inglês
Published: Impact Journals 2020
Subjects:
Research Paper
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7746348/
https://ncbi.nlm.nih.gov/pubmed/33203790
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/aging.104028
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items